"Intelligent" Transformation, Innovation Leadership | The 2nd AI Drug Discovery Conference and AI-Powered Pharma Summit for a Healthy China

Organizer:Shanghai Shengjie Pharmaceutical (Group) Co., Ltd.

Supporting Organizations:Shenzhen XtalPi Technology Co., Ltd., Shiyu Capital

With the rapid development in the fields of biomedicine, life sciences, and information technology, the biopharmaceutical industry is entering a new stage of innovative leapfrogging. Big data and artificial intelligence (AI) technologies have become important drivers accelerating innovation and transformation, demonstrating significant potential in reducing R&D costs, shortening R&D cycles, and improving the success rate of R&D.

Currently, China is at a historic juncture for transitioning from a major pharmaceutical producer to a leading pharmaceutical power. Against the backdrop of the national vigorous implementation of the "Healthy China" strategy and the elevation of artificial intelligence (AI) development to a central governmental priority, research and applications of AI in the pharmaceutical sector have achieved unprecedented progress. As a strategic technology shaping the future and the core driver of a new round of industrial transformation, AI holds significant importance. Timely initiation of planning research on "AI + Pharmaceuticals," tailored to national conditions, is crucial for implementing the "Healthy China" and "Innovation-Driven Development" strategies, and for propelling the pharmaceutical and health industries to become new pillars of the national economy.

To better seize the opportunities of this era, the “2nd AI Drug R&D Conference and Summit on AI-Driven Smart Pharmaceuticals Supporting Healthy China,” hosted by Shanghai Shengjie Pharmaceutical (Group) Co., Ltd. and supported by Shenzhen XtalPi Technology Co., Ltd. and Puyu Capital, is scheduled to be held in Shanghai, China, on April 8–9, 2022. The conference will invite top scientists and entrepreneurs in the field of artificial intelligence from both domestic and international arenas to engage in extensive and in-depth discussions on key topics such as national policies and industry trends, strategic development and R&D strategies for innovative drugs, and frontier hotspots including pharmaceutical big data and artificial intelligence. Leaders and experts from the pharmaceutical regulatory sector, along with senior executives and industry elites involved in innovative drug R&D, project initiation, investment evaluation, and transactions, will gather to conduct thorough analyses and discussions on various conference themes, deliver high-quality presentations, and create more high-value opportunities for exchange and cooperation among Chinese pharmaceutical enterprises.

Standing at the forefront of the times, we officially sound the “assembly call” for innovation in China’s pharmaceutical industry. We hope that pharmacy professionals will join hands to promote the rapid development of AI-driven medicine in China, accelerate the advent of an intelligent society, and benefit human life.

[Conference Venue]No. 2588, Jinxiu Road, Pudong New Area

[About Transportation]

● For the distances and travel times from each departure point to the conference venue, please refer to the figure below:

● During the pandemic, to ensure safe attendance, on-site attendees (including those with a travel history to medium- or high-risk areas for COVID-19 overseas or within China in the past 14 days) must present both a green itinerary code and a green health code for entry.

● Travelers with an asterisk (*) on their itinerary code must provide proof of a negative nucleic acid test taken within 48 hours.